Cantitate/Preț
Produs

Resistance to Targeted ABC Transporters in Cancer: Resistance to Targeted Anti-Cancer Therapeutics, cartea 4

Editat de Thomas Efferth
en Limba Engleză Paperback – 23 aug 2016
This critical review volume explores the theme of ABC transporters in the context of basic cancer research and its role in drug-resistant tumors. The chapters provided complement basic research by including investigations from translational applications to clinical oncology. The development of resistance is a major obstacle in cancer chemotherapy and the field has been moving rapidly in terms of determining the mechanisms for blocking ABC transporter-mediated drug efflux by specific inhibitors and thereby overcoming multidrug resistance. The volume covers these issues in careful detail. Additional topics include the relevance of ABC transporters in resistance to novel and established anticancer drugs and prognosis of patients to compounds, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors and of nanotechnology to combat drug-resistant tumors is also discussed.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 69612 lei  6-8 săpt.
  Springer International Publishing – 23 aug 2016 69612 lei  6-8 săpt.
Hardback (1) 70285 lei  6-8 săpt.
  Springer International Publishing – 7 noi 2014 70285 lei  6-8 săpt.

Din seria Resistance to Targeted Anti-Cancer Therapeutics

Preț: 69612 lei

Preț vechi: 73275 lei
-5% Nou

Puncte Express: 1044

Preț estimativ în valută:
13322 14011$ 11097£

Carte tipărită la comandă

Livrare economică 04-18 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319379968
ISBN-10: 3319379968
Pagini: 310
Ilustrații: X, 300 p. 60 illus., 21 illus. in color.
Dimensiuni: 155 x 235 x 17 mm
Greutate: 0.44 kg
Ediția:Softcover reprint of the original 1st ed. 2015
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Cuprins

Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside.- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis.- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance.- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2.- ABC transporters in cancer stem-like cells.- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer.- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids.- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer.- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors.- Nanotechnology to combat multidrug resistance in cancer.- Drugs affecting epigenetic modifications of ABC transporters.

Notă biografică

Thomas Efferth, Ph.D., is a full Professor and Chair of Pharmaceutical Biology at the University of Mainz in Germany. Dr. Efferth is an expert on ABC transporters and has given over 130 lectures at international conferences. Dr. Efferth has received over 6,000 citations in his career. In addition, Dr. Efferth is on the Editorial Board of 26 journals, including the International Journal of Oncology, Cancer Genomics and Proteomics, Current Medicinal Chemistry, Frontiers in Pharmacology, to name a few. He's also a scientific advisory board member of several institutions, including the German Pharmaceutical Society and the International Institute of Anticancer Research.

Textul de pe ultima copertă

This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed.
The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance—all of these topics and more is explored in this volume.

Caracteristici

Provides up-to-date research on the role of ABC transporters in drug-resistant tumors Examines the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors and of nanotechnology to combat drug-resistant tumors Features chapters which complement basic research with investigations from translational applications to oncology Includes supplementary material: sn.pub/extras